(CercleFinance.com) – AstraZeneca announced on Tuesday the approval in Japan of Evusheld for both the prevention and treatment of severe forms of Covid-19 in the most vulnerable people.
The biopharmaceutical group indicates that the Japanese Ministry of Health, Labor and Welfare has granted special emergency authorization to Evusheld in adults and adolescents at least 12 years old.
In prevention, Evusheld is authorized in the most vulnerable patients who do not respond, or respond insufficiently, to vaccination due to their immunodeficiencies.
As a treatment, Evusheld is approved for adults and adolescents at risk of developing severe forms of the disease that do not require oxygen.
This is the first authorization granted by Evusheld worldwide.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
